Brian Orsinger, CEBS, GBDS, VBS

On July 4, 2025, the “One Big Beautiful Bill Act” (OBBB Act) was signed into law, bringing several notable changes…

Since the first biosimilar was approved by the U.S. Food and Drug Administration (FDA) in 2015, this class of medications…

The cost of health care—and consequently, employee benefits—has been steadily climbing in recent years, creating challenges for businesses and employees…